Navigation Links
Dr. Neal Rouzier Joins BioTE Medical
Date:7/22/2014

DALLAS, July 22, 2014 /PRNewswire/ -- BioTE Medical, a leading provider of hormone replacement therapy using natural, bio-identical hormone pellets, today announced the addition of Dr. Neal Rouzier, MD to the company.   Dr. Rouzier is joining the BioTE Medical Advisory Board as a training physician.     

Dr. Rouzier was residency trained in Family Medicine and Emergency Medicine at UCLA and is a board certified emergency physician still practicing at a large metropolitan trauma center in Southern California.  He is also founder and director of the Preventive Medicine Clinic of Palm Springs where he specializes in optimizing hormones for men and women.  Commenting on the addition of Dr. Rouzier to the BioTE Medical team, BioTE Medical Founder Dr. Gary Donovitz commented, "I've known Dr. Neal Rouzier for years.   His dedication to innovation in the areas of anti-aging and hormone replacement therapy make him a perfect fit with BioTE Medical.  Our growth has been phenomenal in the last 3 years, and with the leadership of people like Dr. Rouzier, we're going to be helping more and more people discover how good life can be when their hormones are balanced."     

Dr. Rouzier stated that he was looking forward to making a contribution to the fast growing BioTE Medical and that he shares Dr. Donovitz's passion for teaching.   He said, "Dr. Donovitz, Dan DeNeui (BioTE COO) and their team have done tremendous work to bring bio-identical hormone replacement to the forefront of people's awareness.   I'm looking forward to helping them bring this innovation to practices in Southern California and other west coast markets.  I'm excited and grateful to be part of BioTE Medical." 

Dan DeNeui, BioTE Medical COO, said the addition of Dr. Rouzier is consistent with BioTE's mission of supporting medical practitioners.  DeNeui, who heads BioTE Medical's monthly training for physicians in Dallas, TX, commented, "The BioTE Method works because it is natural and also because of our training and precision.   Having a person like Dr. Rouzier available for our research and training is invaluable.   His addition underscores our commitment to helping our medical practitioners be successful in all aspects of working with BioTE Medical." 

Dr. Rouzier will also be active in the launching of BioTE Research & Development in 2015.   Dr. Donovitz added, "Dr. Rouzier will be a part of our research & development including the upcoming study regarding the effect of hormone therapy on veterans suffering from Post-Traumatic Stress Disorder (PTSD) and head injuries."

Founded in 2011, BioTE Medical has experienced impressive growth.  Over 600 medical practitioners from 32 states currently offer patients the BioTE method of bio-identical hormone replacement therapy.   Cumulatively, BioTE certified practitioners have treated over 100,000 patients.     

Interviews Available

Contact:
McQ Media 
214-257-8484

Photo - http://photos.prnewswire.com/prnh/20140722/129140


'/>"/>
SOURCE BioTE Medical
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
2. Robert Farrell Joins Bionovos Board of Directors
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. First Choice Rehabilitation Specialists Joins Select Medical
6. Excel Life Sciences Joins DATATRAKs Connect Partner Program
7. Marina Biotech, Inc. Joins OTCQX
8. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
9. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... and SAN DIEGO , Dec. 6, ... appointment of Santosh Kesari , MD, PhD, FANA, ... leverage his experience in neurology and clinical trials to ... cell for treatment of stroke. The AmnioStem product is a ... has previously shown therapeutic activity in animal models of ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International has ... million from the National Institutes of Health,s National ... Division of AIDS (NIAID-DAIDS) to support the manufacturing ... pre-exposure (PreP) agents. Under the seven-year contract, SRI ... development services for candidate HIV-prevention products that emerge ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... company focused on discovery and development of precision treatments for neurodegenerative diseases, ... for Alzheimer’s disease (AD) inhibited the direct neurotoxic effect of prion-like forms ...
(Date:12/5/2016)... Dec. 5, 2016 Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced that ... treatment of Alzheimer,s disease will be presented at the ... Friday, December 9, 2016 in San Diego ... of both simple and complex measures of activities of ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):